John D. Crispino, PhD, MBA
John D. Crispino, PhD, MBA

John D. Crispino, PhD, MBA

Member, St. Jude Faculty

  • Director, Division of Experimental Hematology
  • The Wall Street Committee Endowed Chair

Departments

Divisions

Education

AB (Biology) - Washington University
PhD (Biology) - Massachusetts Institute of Technology,
MBA (Finance and Management/Organizations) - Kellogg School of Management,
Postdoctoral Research Fellow - Harvard Medical School and Children’s Hospital of Boston

Awards & Honors  

  • 1996  Jane Coffin Childs Post-doctoral Fellowship
  • 2000  Burroughs Wellcome Career Development Award
  • 2001  The V Foundation: “V” Scholar Award
  • 2001  American Society of Hematology Junior Faculty Award
  • 2005  Leukemia and Lymphoma Society Scholar Award
  • 2011  Pamela B. Katten Memorial Illinois Leukemia Researcher of the Year
  • 2017  Leukemia and Lymphoma Society Illinois Chapter Researcher of the Year
  • 2018  Leukemia and Lymphoma Society Chairman’s Special Recognition Award

Research Interests

  • Mechanisms of leukemogenesis in children with Down syndrome
  • Role of GATA1 in normal red blood cell and platelet development
  • Development of novel therapies for benign and malignant blood disorders
  • Malignant progression of myelodysplastic and myeloproliferative neoplasms
  • Congenital anemias

Selected Publications

Laurent AP, Siret A, Ignacimouttou C, Panchal K, Diop M, Jenni S, Tsai YC, Roos-Weil D, Aid Z, Prade N, Lagarde S, Plassard D, Pierron G, Daudigeos E, Lecluse Y, Droin N, Bornhauser BC, Cheung LC, Crispino JD, Gaudry M, Bernard OA, Macintyre E, Barin Bonnigal C, Kotecha RS, Geoerger B, Ballerini P, Bourquin JP, Delabesse E, Mercher T, Malinge S. Constitutive activation of RAS/MAPK pathway cooperates with trisomy 21 and is therapeutically exploitable in Down syndrome B-cell leukemia. Clinical Cancer Research pre-published online March 27, 2020.

McNulty M, Crispino JD. Acute Megakaryocytic Leukemia. Cold Spring Harbor Perspectives in Medicine 10(2):a034884, 2020.

Ling T, Crispino JD. GATA1 mutations in red cell disorders. IUBMB Life 72:106-118, 2020.  

Ling T, Birger Y, Stankiewicz MJ, Ben-Haim N, Kalisky T, Rein A, Kugler E, Chen W, Fu C, Zhang K, Patel H, Sikora JW, Goo YA, Kelleher N, Zou L, Izraeli S, Crispino JD. Chromatin occupancy and epigenetic analysis reveal new insights into the function of the GATA1 N-terminus in erythropoiesis. Blood 134:1619-1631, 2019. PMC6871310

Labuhn M, Perkins K, Matzk S, Varghese L, Garnett C, Papaemmanuil E, Metzner M, Kennedy A, Amstislavskiy V, Risch T, Bhayadia R, Samulowski D, Hernandez DC, Stoilova B, Iotchkova V, Oppermann U, Scheer C, Yoshida K, Schwarzer A, Taub J, Crispino JD, Weiss MJ, Hayashi A, Taga T, Ito E, Ogawa S, Reinhardt D, Yaspo ML, Campbell PJ, Roberts I, Constantinescu S, Vyas P, Heckl D, Klusmann JH. Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. Cancer Cell 36:123-138, 2019. PMC6863161

Woods B, Yang, Q, Chiu, S, Marinaccio C, Fu C, Gu L, Bulic M, Rappaport F, Levine RL, Crispino JD, Wen Q. Activation of JAK/STAT signaling in megakaryocytes sustains myeloproliferation in vivo. Clinical Cancer Research 25:5901-5912, 2019. PMC6774846

Gangat N, Marinaccio C, Swords R, Watts JM, Gurbuxani S, Rademaker A, Fought AJ, Frankfurt O, Altman JK, Wen QJ, Farnoud N, Famulare CA, Patel A, Tapia R, Vallapureddy RR, Barath S, Graf A, Handlogten A, Zblewski D, Patnaik MM, Al-Kali A, Dinh YT, Englund Prahl K, Patel S, Nobrega JC, Tejera D, Thomassen A, Gao J, Ji P, Rampal RK, Giles FJ, Tefferi A, Stein B, Crispino JD. Aurora kinase A inhibition provides clinical benefit, normalizes megakaryocytes and reduces bone marrow fibrosis in patients with myelofibrosis: a phase 1 trial. Clinical Cancer Research 25:4898-4906, 2019. PMC- N/A

Schieber M, Crispino JD, Stein B. Myelofibrosis in 2018: Moving beyond JAK2. Blood Cancer Journal 9:74, 2019. doi: 10.1038/s41408-019-0236-2. PMC6739355

Zhao Z, Wang L, Volk AG, Birch NW, Stoltz KL, Bartom ET, Marshall SA, Rendleman EJ, Nestler CM, Shilati J, Schiltz GE, Crispino JD, Shilatifard A. Regulation of MLL/COMPASS stability through its proteolytic cleavage by taspase1 as a possible approach for clinical therapy of leukemia. Genes & Development 33:61-74, 2019. PMC6317322

Jin Q, Martinez C, Arcipowski K, Zhu Y, Gutierrez Diaz B, Wang K, Johnson M, Volk A, Wang F, Wu J, Grove C, Wang H, Sokirniy I, Thomas P, Goo Y, Abshiru N, Hijiya N, Peirs S, Vandamme N, Berx G, Goosens S, Marshall S, Rendleman E, Takahashi Y-h, Wang L, Rawat R, Bartom E, Collins C, Van Vlierberghe P, Strikoudis A, Kelly S, Ueberheide B, Mantis C, Kandela I, Bourquin J-P, Bornhauser B, Serafin V, Bresolin S, Paganin M, Accordi B, Basso G, Kelleher N, Weinstock J, Kumar S, Crispino J, Shilatifard A, Ntziachristos P. USP7 cooperates with NOTCH1 to drive the oncogenic transcriptional program in T cell leukemia. Clinical Cancer Research 25:222-239, 2019. PMC6320313

Volk A, Liang K, Suraneni P, Li X, Zhao J, Bulic M, Marshall S, Pilakanti K, Malinge S, Taub J, Ge Y, Rao S, Bartom E, Shilatifard A, Crispino JD. A CHAF1Bdependent molecular switch in hematopoiesis and leukemia pathogenesis. Cancer Cell 34:707-723, 2018. PMC6235627

Suraneni PK, Corey SJ, Hession MJ, Ishaq R, Awomolo A, Hasan S, Debili N, Crispino JD, Eklund EA, Chen Y. Dynamins 2 and 3 control the migration of human megakaryocytes by regulating CXCR4 surface expression and ITGB1 activity. Blood Advances 2:3540-3552, 2018. PMC6290100

Payton M, Cheung H-K, Marinaccio C, Ninniri MSS, Wayne WC, Hanestad K, Crispino J, Juan G, Coxon A. Dual targeting of aurora kinases with AMG 900 exhibits potent preclinical activity against acute myeloid leukemia with distinct post-mitotic outcomes. Molecular Cancer Therapeutics 17:2575-2585, 2018. PMC6279493

Khan I, Halasi M, Patel A, Schultz R, Kalakota N, Chen Y-H, Aardsma N, Liu L, Crispino JD, Mahmud N, Frankfurt O, Gartel AL. FOXM1 contributes to treatment failure in acute myeloid leukemia. JCI Insight 3(15), 2018. pii:121583. PMC6129129

Melo-Cardenas J, Xu Y, Wei J, Tan C, Kong S, Gao B, Montauti E, Kirsammer G, Licht JD, Yu J, Ji P, Crispino J, Fang D. Usp22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1 dependent mechanism. Blood 132:423-434, 2018. PMC6071563

Yang X, Lu B, Sun X, Han C, Fu C, Xu K, Wang M, Li D, Chen Z, Opal P, Wen Q, Crispino JD, Wang QF, Huang Z. ANP32A regulates histone H3 acetylation and promotes leukemogenesis. Leukemia 32:1587-1597, 2018.

Zhao B, Mei, Y, Sumagin R, Yang J, Thorsheim C, Zhao L, Stalker T, Wen Q, Crispino, JD, Abrams CS, Ji P. Pleckstrin-2 plays an essential role in the pathogenesis of JAK2V617F-induced myeloproliferative neoplasms. J Clin Invest 128:125-140, 2018. PMC5749534

Nitulescu II, Meyer SC, Wen QJ, Crispino JD, Lemieux ME, Levine RL, Pelish HE, Shair MD. Mediator kinase phosphorylation of STAT1 S727 promotes growth of neoplasms with JAK-STAT activation. EBioMedicine Dec;26:112-125, 2017. PMC5832629

Sun X, Lu B, Han C, Qiu W, Jin Q, Li D, Li Q, Yang Q, Wen Q, Opal, P, Kini AR, Crispino JD, Huang Z. ANP32A dysregulation contributes to abnormal megakaryopoiesis in acute megakaryoblastic leukemia. Blood Cancer Journal 7:661, 2017. PMC5802576

Anso E, Weinberg S, Diebold L, Thompson B, Malinge S, Schumacker P, Liu X, Zhang Y, Shao Z, Steadman M, Marsh K, Xu J, Crispino J, Chandel N. The mitochondrial respiratory chain is essential for hematopoietic stem cell function. Nature Cell Biology 19:614-625, 2017. PMC5474760

Mosoyan G, Kraus T, Ye F, Eng K, Crispino JD, Hoffman R, Iancu-Rubin C. Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis. Leukemia 31:2458-2467, 2017. PMC5985670

Crispino JD, Horwitz M. GATA factor mutations in hematologic disease. Blood 129:2103-2110, 2017. PMC5391620

Thirant C, Ignacimouttou C, Lopez C, Le Mouël L, Thiollier C, Siret A, Dessen P, Aid Z, Rivière J, Rameau P, Lefebvre C, Khaled M, Leverger G, Ballerini P, Petit A, Raslova H, Carmichael CL, Kile BT, Soler E, Crispino JD, Wichmann C, Pflumio F, Schwaller J, Vainchenker W, Lobry C, Droin N, Bernard OA, Malinge S, Mercher T. ETO2-GLIS2 hijacks transcriptional complexes to drive cellular identity and self-renewal in pediatric acute megakaryoblastic leukemia. Cancer Cell 31:452-465, 2017. (PMC N/A)

Hu D, Gao X, Cao K, Morgan MA, Mas G, Smith ER, Volk AG, Bartom ET, Crispino JD, Di Croce L, Shilatifard A. Not All H3K4 Methylations Are Created Equal: Mll2/COMPASS Dependency in Primordial Germ Cell Specification. Mol Cell 65:460-475, 2017. PMC5404503

Gilles L, Arslan AD, Marinaccio C, Wen QJ, Arya P, McNulty M, Yang Q, Zhao JC, Konstantinoff K, Lasho T, Pardanani A, Stein B, Plo I, Sundaral S, Wickrema, A, Migliaccio, A, Gurbuxani, S, Vainchenker W, Platanias L, Tefferi A, Crispino JD. Down-regulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. Journal of Clinical Investigation 127:1316-1320, 2017. PMC5373858

Liang K, Volk AG, Haug JS, Marshall SA, Woodfin AR, Bartom E, Gilmore JM, Florens L, Washburn MP, Sullivan KD, Espinosa JM, Cannova J, Zhang J, Smith ER, Crispino JD, Shilatifard A. Therapeutic targeting of MLL degradation pathway in MLL rearranged leukemia. Cell 168:59-72, 2017. PMC5351781

Fisher J, Peterson J, Reimer M, Stelloh C, Pulakanti K, Gerbec ZJ, Abel AM, Strouse JM, Strouse C, McNulty M, Malarkannan S, Crispino JD, Milanovich S, Rao S. The cohesin subunit Rad21 is a negative regulator of hematopoietic self-renewal through epigenetic repression of HoxA7 and HoxA9. Leukemia 31:712-719, 2017. PMC5332284

Lee P, Bhansali R, Izraeli S, Hijiya N, Crispino JD. The Biology, Pathogenesis and Clinical Aspects of Acute Lymphoblastic Leukemia in Children with Down syndrome. Leukemia 30:1816-1823, 2016. PMC5434972

Last update: July 2020

For updates on COVID-19, please read.